Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of LY3209590 in Healthy Participants
NCT05615532Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1D) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at Day 65. Started Nov 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05615532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615532.